Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder.

The Journal of clinical psychiatry - 1 May 2007

DelBello Melissa P, Adler Caleb M, Whitsel Rachel M, Stanford Kevin E, Strakowski Stephen M

Abstract excerpt

OBJECTIVE: To investigate the effectiveness and tolerability of quetiapine for the treatment of adolescents at high risk for developing bipolar I disorder. METHOD: Twenty adolescents (aged 12-18 years) with mood symptoms that did not meet DSM-IV-TR criteria for bipolar I disorder and who had at least one first-degree relative with bipolar I disorder were recruited from August 2003 to June 2005 to participate in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bipolar Disorder

Share to Genetic Predisposition to Disease

Share to Mood Disorders

Share to Single-Blind Method

Source

Identifiers

PMID: 17503991
DOI: 10.4088/jcp.v68n0520

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder.PMID 17503991Read ↗

A Pharmacologic Algorithm for Youth Who Are at High Risk for Bipolar Disorder.Semantic proximity Read ↗

A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder.Semantic proximity Read ↗

Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder.Semantic proximity Read ↗

Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysisSemantic proximity Read ↗

Medical management of pediatric mood disorders.Semantic proximity Read ↗

[Management of bipolar 1 disorder in children and adolescents].Semantic proximity Read ↗

Mood stabilizers in the treatment of juvenile bipolar disorder. Advances and controversies.Semantic proximity Read ↗

Biologic basis of bipolar disorder in children and adolescents.Semantic proximity Read ↗

Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.Semantic proximity Read ↗

Pediatric bipolar disorder comes of age.Semantic proximity Read ↗

Pharmacological management of new-onset bipolar disorder.Semantic proximity Read ↗

[Child and adolescent bipolar disorder].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.